BOOK
Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics - E-Book
(2010)
Additional Information
Book Details
Abstract
An estimated 234,000 new cases of prostate cancer will be diagnosed in the United States this year, making it one of the most common cancers affecting American men; however, it can be a controversial disease to diagnose and treat now that there is research abounding for both “watchful waiting and aggressive treatments. Dr. Oh supplies balanced information, with articles on: Prostate Cancer: To Screen or Not To Screen?; High Intensity Focused Ultrasound: Ready for Primetime?; The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy; Primary and Salvage Prostate Cancer Cryotherapy; and The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy, to name a few. The state-of-the art information presented in this issue make is must-have for all urologists.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contributors | iii | ||
| Contents | vii | ||
| Urologic Clinics of North America | xi | ||
| Preface | xii | ||
| Chapter 1. Prostate Cancer: To Screen or Not to Screen? | 1 | ||
| THE BURDEN OF PROSTATE CANCER | 1 | ||
| WHY SCREEN: RATIONALE FOR SCREENING | 2 | ||
| LEAD TIMES AND OVERDIAGNOSIS | 2 | ||
| PROSTATE CANCER SCREENING TOOLS | 3 | ||
| TO SCREEN OR NOT TO SCREEN USING PSA: THE PLCO AND ERSPC STUDIES | 4 | ||
| EFFECT OF SCREENING FOR PROSTATE CANCER ON QUALITY OF LIFE | 5 | ||
| WHO SHOULD BE SCREENED? | 7 | ||
| WHAT IS A CLINICIAN TO DO? | 7 | ||
| SUMMARY | 7 | ||
| REFERENCES | 7 | ||
| Chapter 2. Chemoprevention of Prostate Cancer | 11 | ||
| RATIONALE FOR CHEMOPREVENTION OF PROSTATE CANCER | 12 | ||
| CHEMOPREVENTION TRIALS IN PROSTATE CANCER | 13 | ||
| CHEMOPREVENTION AND PROSTATE CANCER RISK | 18 | ||
| SUMMARY | 19 | ||
| REFERENCES | 19 | ||
| Chapter 3. Update on Prostate Imaging | 23 | ||
| ULTRASOUND | 23 | ||
| COMPUTED TOMOGRAPHY | 23 | ||
| MAGNETIC RESONANCE IMAGING | 23 | ||
| ACKNOWLEDGMENTS | 24 | ||
| REFERENCES | 24 | ||
| Chapter 4. High-intensity Focused Ultrasound: Ready for Primetime | 27 | ||
| HIFU TECHNIQUE | 28 | ||
| CURRENT MARKET PRODUCTS | 28 | ||
| MECHANISM OF ACTION | 29 | ||
| PATIENT SELECTION | 30 | ||
| TREATMENT OUTCOMES | 31 | ||
| FOLLOW-UP | 32 | ||
| COMPLICATIONS | 32 | ||
| SUMMARY | 32 | ||
| REFERENCES | 33 | ||
| Chapter 5. Overcoming the Learning Curve for Robotic-assisted Laparoscopic Radical Prostatectomy | 37 | ||
| LEARNING CURVE: THE CHALLENGE OF RADICAL PROSTATECTOMY | 38 | ||
| TECHNICAL CHALLENGES OF RALP | 39 | ||
| THE BRIGHAM & WOMEN’S HOSPITAL TECHNIQUE | 41 | ||
| TIPS FOR THE BEGINNER | 44 | ||
| REFERENCES | 45 | ||
| Chapter 6. The Case for Open Radical Prostatectomy | 49 | ||
| COST | 51 | ||
| PERIOPERATIVE OUTCOMES | 51 | ||
| ONCOLOGICAL OUTCOMES | 52 | ||
| FUNCTIONAL OUTCOMES | 53 | ||
| SUMMARY | 54 | ||
| REFERENCES | 54 | ||
| Chapter 7. Controversies Surrounding Lymph Node Dissection for Prostate Cancer | 57 | ||
| DETERMINING IN WHOM TO PERFORM PELVIC LYMPHADENECTOMY | 57 | ||
| EVALUATING THE ROLE OF IMAGING IN IDENTIFYING LYMPH NODE INVASION | 58 | ||
| EXAMINING THE IMPORTANCE OF THE ANATOMIC TEMPLATE | 59 | ||
| TAKING INTO ACCOUNT THE SURGICAL APPROACH | 60 | ||
| ASSESSING THE RATIONALE FOR PELVIC LYMPH NODE DISSECTION | 61 | ||
| CONTEMPLATING THE RISKS OF PELVIC LYMPH NODE DISSECTION | 62 | ||
| SUMMARY | 63 | ||
| ACKNOWLEDGMENTS | 63 | ||
| REFERENCES | 63 | ||
| Primary and Salvage Cryotherapy for Prostate Cancer | 67 | ||
| CRYOINJURY | 67 | ||
| FACTORS AFFECTING TISSUE DESTRUCTION DURING CRYOTHERAPY | 67 | ||
| SURVEILLANCE AFTER CRYOTHERAPY | 69 | ||
| PRIMARY CRYOTHERAPY | 70 | ||
| FOCAL CRYOTHERAPY | 71 | ||
| SALVAGE CRYOTHERAPY | 74 | ||
| OUTCOMES | 75 | ||
| COMPLICATIONS OF CRYOTHERAPY | 76 | ||
| SUMMARY | 78 | ||
| REFERENCES | 79 | ||
| Chapter 8. Current Topics in the Treatment of Prostate Cancer with Low-Dose-Rate Brachytherapy | 83 | ||
| THE DEVELOPMENT OF A REAL-TIME ULTRASOUND-GUIDED IMPLANT TECHNIQUE | 83 | ||
| BRACHYTHERAPY AND RADIATION DOSE | 84 | ||
| TRIMODALITY THERAPY FOR HIGH-RISK PROSTATE CANCER | 85 | ||
| LONG-TERM OUTCOMES | 88 | ||
| BRACHYTHERAPY-ASSOCIATED MORBIDITY | 88 | ||
| REFERENCES | 93 | ||
| Chapter 9. Neoadjuvant and Adjuvant Therapies in Prostate Cancer | 97 | ||
| HT | 98 | ||
| CHEMOTHERAPY | 100 | ||
| ADJUVANT RADIOTHERAPY | 101 | ||
| SUMMARY | 102 | ||
| REFERENCES | 102 | ||
| Chapter 10. Novel Targeted Therapies for Prostate Cancer | 105 | ||
| ANDROGEN RECEPTOR SIGNALING | 105 | ||
| VASCULAR ENDOTHELIAL GROWTH FACTOR AND RECEPTOR | 107 | ||
| APOPTOSIS | 108 | ||
| CHAPERONE PROTEINS | 109 | ||
| INSULINLIKE GROWTH FACTOR-1 RECEPTOR | 110 | ||
| PHOSPHATIDYLINOSITOL-3-KINASE (PI3K)-AKT SIGNALING PATHWAY | 110 | ||
| BONE TARGETING | 111 | ||
| CYTOTOXIC AGENTS | 113 | ||
| SUMMARY | 114 | ||
| REFERENCES | 114 | ||
| Chapter 11. Immunotherapy for Prostate Cancer: An Emerging Treatment Modality | 121 | ||
| ACTIVE IMMUNOTHERAPY FOR PROSTATE CANCER | 122 | ||
| COMBINING CONVENTIONAL THERAPY WITH ACTIVE IMMUNOTHERAPY | 124 | ||
| IMMUNE MODULATORS (BRAKES AND ACCELERATORS) | 125 | ||
| MONOCLONAL ANTIBODIES | 126 | ||
| SUMMARY | 126 | ||
| REFERENCES | 127 | ||
| Chapter 12. Blood and Tissue Biomarkers in Prostate Cancer: State of the Art | 131 | ||
| TISSUE BIOMARKERS | 132 | ||
| BLOOD BIOMARKERS | 135 | ||
| SUMMARY | 137 | ||
| REFERENCES | 137 | ||
| Index | 143 |